HIV and the body: A review of multidisciplinary management

HIV Medicine

Volumn 11, Issue SUPPL. 2, 2010, Pages 1-8

  Rockstroh, J ^a   Guaraldi, G ^b   Deray, G ^c  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Age associated comorbidity; Monitoring; Multidisciplinary management; Screening

Indexed keywords

ANTIVIRUS AGENT; PROTEINASE INHIBITOR; RITONAVIR;

ANTIVIRAL THERAPY; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; COMORBIDITY; DIABETES MELLITUS; DYSLIPIDEMIA; EXERCISE; GLUCOSE INTOLERANCE; HEALTH PROGRAM; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; KIDNEY DISEASE; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; LIVER DISEASE; MASS SCREENING; MEDICAL EDUCATION; METABOLIC DISORDER; MIXED INFECTION; MORBIDITY; MORTALITY; OSTEOPENIA; OSTEOPOROSIS; PATIENT CARE; PATIENT MONITORING; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOKING CESSATION;

ADOLESCENT; ADULT; AGE FACTORS; AGE OF ONSET; AGING; ANTI-RETROVIRAL AGENTS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; COMORBIDITY; DEVELOPED COUNTRIES; DIABETES MELLITUS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; EDUCATION, MEDICAL, CONTINUING; FEMALE; GLUCOSE INTOLERANCE; HEPATITIS, VIRAL, HUMAN; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HUMANS; KIDNEY DISEASES; LIFE STYLE; LIVER DISEASES; MALE; MASS SCREENING; MIDDLE AGED; OSTEOPOROSIS; PATIENT CARE TEAM; REFERRAL AND CONSULTATION; RISK FACTORS; YOUNG ADULT;

EID: 77956492557     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00859.x     Document Type: Review

References (41)

1. Lohse N, Hansen AB, Gerstoft J, Obel N. Improved survival in HIV-infected persons: consequences and perspectives. J Antimicrob Chemother 2007, 60:461-463.
2. Lohse N, Hansen AB, Pedersen G. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007, 146:87-95.
3. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006, 166:1632-1641. DAD Study Group.
4. Appay V, Almeida JR, Sauce D, Autran B, Papagno L. Accelerated immune senescence and HIV-1 infection. Exp Gerontol 2007, 42:432-437.
5. http://www.europeanaidsclinicalsociety.org/guidelines.asp, European AIDS Clinical Society (EACS)., Clinical management and treatment of HIV infected adults in Europe. On the prevention and management of metabolic diseases in HIV. EACS Guidelines version 5. Available at, (accessed May 2010).
6. Graham CS, Baden LR, Yu E. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001, 33:562-569.
7. Rockstroh JK, Mocroft A, Soriano V. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005, 192:992-1002.
8. Salmon D, Robain M, Rockstroh JK, Benhamou Y. Therapeutic management of hepatitis and HIV infection in co-infected patients: results of a survey performed before the 2005 Consensus Conference. J Hepatol 2006, 44:S2-S5.
9. Guaraldi G, Murri R, Orlando G. Lipodystrophy and quality of life of HIV-infected persons. AIDS Rev 2008, 10:152-161.
10. Crum-Cianflone N, Dilay A, Collins G. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr 2009, 50:464-473.
11. Pao V, Lee GA, Grunfeld C. HIV therapy, metabolic syndrome, and cardiovascular risk. Curr Atheroscler Rep 2008, 10:61-70.
12. Currier JS, Taylor A, Boyd F. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003, 33:506-512.
13. Guaraldi G, Orlando G, Squillace N. Multidisciplinary approach to the treatment of metabolic and morphologic alterations of HIV-related lipodystrophy. HIV Clin Trials 2006, 7:97-106.
14. Stephan C, Carlebach A, Haberl A. Long term HIV Infection as an independent risk factor for early atherosclerosis. 13th Conference on Retroviruses and Opportunistic Infections. Denver, USA, February 2006 [Abstract 738]
15. El-Sadr WM, Mullin CM, Carr A. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naïve cohort. HIV Med 2005, 6:114-121.
16. Malik S, Wong ND, Franklin SS. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004, 110:1245-1250.
17. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005, 112:3066-3072.
18. Dubé MP, Parker RA, Mulligan K. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis 2000, 31:1467-1475.
19. Carr A, Samaras K, Burton S. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
20. Mehta SH, Moore RD, Thomas DL, Chaisson RE, Sulkowski MS. The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. J Acquir Immune Defic Syndr 2003, 33:577-584.
21. Currier JS, Boyd F, Kawabata H, Dezii C, Burtcel B, Hodder S. Incidence, prevalence, and pathogenic correlates of insulin resistance and lipodystrophy syndrome. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, USA, February 2002 [Abstract 677]
22. Crane HM, Van Rompaey SE, Kitahata MM. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS 2006, 20:1682-1683.
23. Gazzaruso C, Bruno R, Garzaniti A. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens 2003, 21:1377-1382.
24. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected major risk factors and global and regional burden of disease. Lancet 2002, 360:1347-1360. for the Comparative Risk Assessment Collaborating Group.
25. Gardner LI, Klein RS, Szczech LA. Rates and risk factors for condition-specific hospitalizations in HIV-infected and uninfected women. J Acquir Immune Defic Syndr 2003, 34:320-330.
26. Wyatt CM, Arons RR, Klotman PE, Klotman ME. Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. AIDS 2006, 20:561-565.
27. Wyatt CM, Klotman PE. HIV-associated nephropathy in the era of antiretroviral therapy. Am J Med 2007, 120:488-492.
28. Schwartz EJ, Szczech LA, Ross MJ, Klotman ME, Winston JA, Klotman PE. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol 2005, 16:2412-2420.
29. Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004, 18:541-546.
30. Brown TT, Quagash RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006, 20:2165-2174.
31. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008, 93:3499-3504.
32. Lundgren JD, Battegay M, Behrens G. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 2008, 9:72-81.
33. Rockstroh JK, Bhagani S, Benhamou Y. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008, 9:82-88.
34. Brook G, Main J, Nelson M. British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. HIV Med 2010, 11:1-30.
35. http://www.ahrq.gov/clinic/cps3dix.htm, US Preventive Services Task Force., Heart and vascular diseases. Available at, heartvasc (accessed May 2010).
36. Friis-Møller N, Weber R, Reiss P. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy: Results from the DAD study. AIDS 2003, 17:1179-1193.
37. Dubé MP, Stein JH, Aberg JA. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003, 37:613-627.
38. Gupta SK, Eustace JA, Winston JA. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005, 40:1559-1585.
39. Rho M, Perazella MA. Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients. Curr Drug Saf 2007, 2:147-154.
40. Calza L, Manfredi R, Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 2004, 53:10-14.
41. Fantoni M, Del Borgo C, Autore C. Evaluation and management of metabolic and coagulative disorders in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2003, 17((Suppl 1)):S162-S169.